Mancini Anthony 的 Form 4 申報
Revolution Medicines, Inc.RVMD，2026/9/14 申報
- 申報編號
- 0002124509-26-000004
- 申報時間
- 2026/9/14 18:03 ET
- 交易日
- 2026/9/10
- 申報延遲
- 4 天
- 10b5-1 計畫
- 有勾選
這份申報列了 6 筆非衍生性交易、1 筆衍生性交易。公開市場賣出合計 $315.4 萬。交易後 4 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Mancini AnthonyCIK 0002124509 | 高階主管（見申報備註） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/9/10 | Common Stock | M行使選擇權取得 | +9,363 | $33.62 | +$314,784.06 | 59,338 | 直接 | |
| 2026/9/10 | Common Stock | S賣出處分 | −6,019 | $203.28F2 | −$1,223,568.8 | 53,319 | 直接 | |
| 2026/9/10 | Common Stock | S賣出處分 | −5,530 | $204.14F3 | −$1,128,870.42 | 47,789 | 直接 | |
| 2026/9/10 | Common Stock | S賣出處分 | −2,420 | $205.05F4 | −$496,224.15 | 45,369 | 直接 | |
| 2026/9/10 | Common Stock | S賣出處分 | −1,179 | $206.10F5 | −$242,991.31 | 44,190 | 直接 | |
| 2026/9/10 | Common Stock | S賣出處分 | −300 | $207.17F6 | −$62,151.99 | 43,890 | 直接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/9/10 | Common Stock | M行使選擇權處分 | −9,363 | $0.00 | $0 | 96,746 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F2
The transaction was executed in multiple trades at prices ranging from $202.64 to $203.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F3
The transaction was executed in multiple trades at prices ranging from $203.64 to $204.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F4
The transaction was executed in multiple trades at prices ranging from $204.64 to $205.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F5
The transaction was executed in multiple trades at prices ranging from $205.85 to $206.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F6
The transaction was executed in multiple trades at prices ranging from $207.12 to $207.28, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
備註
Chief Global Commercialization Officer